FDA Approves Less Frequent Treatment Regimen for Imfinzi in NSCLC, Bladder Cancer
News
The U.S. Food and Drug Administration (FDA) has approved a new dosing regimen for Imfinzi (durvalumab) for the treatment of certain non-small cell lung cancer (NSCLC) and bladder cancer patients. Granted under priority ... Read more